As oncology moves toward bladder-sparing approaches, even highly effective systemic therapies won't be enough. To prevent local relapse and truly avoid cystectomy, a bladder-directed component, such as an intravesical therapy, will be a necessary part of the long-term treatment strategy.
The REDUCE trial demonstrated that for MCRPC patients with bone metastases, administering denosumab every 12 weeks is non-inferior to the standard 4-week schedule. This practice-changing finding reduces side effects, patient burden, and healthcare costs without sacrificing efficacy.
The varying outcomes of two similar Lilly ADCs (LY405/LY410) demonstrated that how a patient's body metabolizes the drug's payload is a critical factor. Absence of the CYP2D6 enzyme, crucial for a Topo-one payload, led to severe toxicity and death, highlighting a key variable beyond the linker and target.
The Proteus trial's requirement of 2,000 patients highlights a fundamental issue in adjuvant therapy: to prove a modest benefit, a vast number of patients who may already be cured by surgery must be treated. This means many participants endure toxic therapy with no personal benefit, raising ethical concerns.
As effective treatments like EV Pembro become the standard of care in oncology, it is no longer ethically feasible to conduct randomized trials for new "me-too" drugs against the outdated platinum chemotherapy standard in many markets. This severely limits development pathways for fast-follower drugs.
Multiple perioperative studies like Ambassador and Ramparts show no significant quality of life difference between active drugs with known side effects and placebo. This recurring finding suggests that current QoL measurement tools are not sensitive enough to capture the real, long-term toxicities patients experience.
A new framework categorizes adjuvant therapy toxicity into tiers like "significant short-term" and "life-changing," moving beyond abstract CTC grades. This approach better captures the real-world patient experience, enabling more meaningful conversations about the potential for severe, long-lasting harm.
The impressive 68% pathological complete response (pCR) in the SAKK neoadjuvant bladder cancer study may be misleading. Such high rates in single-arm trials are often driven by patient selection biases, such as enrolling patients with earlier T2 disease and those who've had thorough initial surgeries.
Current quality of life (QoL) studies are inherently biased. They stop collecting data from patients who discontinue treatment due to severe side effects. This means the final analysis primarily reflects the experience of patients who tolerated the drug, failing to capture the worst outcomes and painting an overly optimistic picture.